# Pharmacokinetics of LEO 43204 Gel in Actinic Keratosis Administered Under Maximal Use Conditions

> **NCT02424305** · PHASE1 · COMPLETED · sponsor: **LEO Pharma** · enrollment: 60 (actual)

## Conditions studied

- Actinic Keratosis

## Interventions

- **DRUG:** LEO 43204 gel 0.018%
- **DRUG:** LEO 43204 gel 0.1%
- **DRUG:** LEO 43204 gel 0.037%

## Key facts

- **NCT ID:** NCT02424305
- **Lead sponsor:** LEO Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2015-07
- **Final completion:** 2015-07
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02424305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02424305, "Pharmacokinetics of LEO 43204 Gel in Actinic Keratosis Administered Under Maximal Use Conditions". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02424305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*